Leveraging on-table MR soft tissue imaging, MRIdian allows oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that’s simply unavailable with conventional IGRT technologies.
Combining the latest innovations in precision radiation delivery, ground-breaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology.
ViewRay Announces Pricing of Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY) announced the pricing of an underwritten public offering of 16,216,217 shares of common stock at a price to the public of $9.25 per share, for gross proceeds of $150 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.
ViewRay Announces Proposed Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY) today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by ViewRay.
ViewRay Reports Second Quarter 2018 Financial Results
ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2018. The Company is reiterating its financial guidance for the full year 2018.
A new kind of medical technology company—ViewRay® Inc. designs, manufactures and markets MRIdian, the world’s first MRI-Guided radiation therapy system to image and treat cancer patients simultaneously.
Contact Us Today To Learn More Contact
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy